Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis.
<h4>Background</h4>Depression is a common non-motor symptom in patients with Parkinson's disease (PD). There are many kinds of antidepressants being used, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0076651 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849319416692473856 |
|---|---|
| author | Jinling Liu Jiangchuan Dong Lei Wang Ying Su Peng Yan Shenggang Sun |
| author_facet | Jinling Liu Jiangchuan Dong Lei Wang Ying Su Peng Yan Shenggang Sun |
| author_sort | Jinling Liu |
| collection | DOAJ |
| description | <h4>Background</h4>Depression is a common non-motor symptom in patients with Parkinson's disease (PD). There are many kinds of antidepressants being used, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and Dopamine agonists which are suggested as alternative antidepressants for the treatment of depression in PD. Which one should we choose first? Literatures have shown inconsistent results.<h4>Methods</h4>We conducted a network meta-analysis of randomized controlled trials to compare the efficacy and acceptability of therapeutic methods for the treatment of depression in Parkinson's disease.<h4>Results</h4>We used the odds ratios (OR) as effect size firstly and the results indicated no statistical significance between each compared intervention. Then we used the logarithm of the individual odds ratios as effect size. With efficacy of TCAs as the standard of comparison, the degree of incoherence (a measure of how closely the entire network fits together) was small (ω = 4.824827e-05). The logor were: SSRIs -0.69 (95% CI -1.28- -0.10); Pramipexole -0.73 (-1.71- -0.26); Pergolide -1.97 (-3.67- 0.27); SNRIs -0.86 (-1.86- 0.15); Placebo -1.24 (-1.99- -0.50). With Placebo as the standard of comparison, the logor were: TCAs 1.24 (0.50- 1.99); SSRIs 0.55 (-0.03- 1.13); Pramipexole 0.51 (-0.12- 1.15); Pergolide -0.73 (-2.25- 0.80); SNRIs 0.38 (-0.42- 1.19); TCAs, pramipexole, pergolide and SNRIs showed better profile of acceptability, leading to significant fewer discontinuations than that of SSRIs.<h4>Conclusions</h4>There is insufficient evidence to support antidepressant efficacy for SSRIs, pramipexole, pergolide and SNRIs. TCAs might be the best choice when starting antidepressant treatment in patients of Parkinson's disease because it has the most favorable balance between benefits and acceptability, followed by pramipexole and SNRIs, SSRIs might be the last choice. |
| format | Article |
| id | doaj-art-94e9f7158e284da69bf3b314c98f0a56 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-94e9f7158e284da69bf3b314c98f0a562025-08-20T03:50:27ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7665110.1371/journal.pone.0076651Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis.Jinling LiuJiangchuan DongLei WangYing SuPeng YanShenggang Sun<h4>Background</h4>Depression is a common non-motor symptom in patients with Parkinson's disease (PD). There are many kinds of antidepressants being used, such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and Dopamine agonists which are suggested as alternative antidepressants for the treatment of depression in PD. Which one should we choose first? Literatures have shown inconsistent results.<h4>Methods</h4>We conducted a network meta-analysis of randomized controlled trials to compare the efficacy and acceptability of therapeutic methods for the treatment of depression in Parkinson's disease.<h4>Results</h4>We used the odds ratios (OR) as effect size firstly and the results indicated no statistical significance between each compared intervention. Then we used the logarithm of the individual odds ratios as effect size. With efficacy of TCAs as the standard of comparison, the degree of incoherence (a measure of how closely the entire network fits together) was small (ω = 4.824827e-05). The logor were: SSRIs -0.69 (95% CI -1.28- -0.10); Pramipexole -0.73 (-1.71- -0.26); Pergolide -1.97 (-3.67- 0.27); SNRIs -0.86 (-1.86- 0.15); Placebo -1.24 (-1.99- -0.50). With Placebo as the standard of comparison, the logor were: TCAs 1.24 (0.50- 1.99); SSRIs 0.55 (-0.03- 1.13); Pramipexole 0.51 (-0.12- 1.15); Pergolide -0.73 (-2.25- 0.80); SNRIs 0.38 (-0.42- 1.19); TCAs, pramipexole, pergolide and SNRIs showed better profile of acceptability, leading to significant fewer discontinuations than that of SSRIs.<h4>Conclusions</h4>There is insufficient evidence to support antidepressant efficacy for SSRIs, pramipexole, pergolide and SNRIs. TCAs might be the best choice when starting antidepressant treatment in patients of Parkinson's disease because it has the most favorable balance between benefits and acceptability, followed by pramipexole and SNRIs, SSRIs might be the last choice.https://doi.org/10.1371/journal.pone.0076651 |
| spellingShingle | Jinling Liu Jiangchuan Dong Lei Wang Ying Su Peng Yan Shenggang Sun Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. PLoS ONE |
| title | Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. |
| title_full | Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. |
| title_fullStr | Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. |
| title_full_unstemmed | Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. |
| title_short | Comparative efficacy and acceptability of antidepressants in Parkinson's disease: a network meta-analysis. |
| title_sort | comparative efficacy and acceptability of antidepressants in parkinson s disease a network meta analysis |
| url | https://doi.org/10.1371/journal.pone.0076651 |
| work_keys_str_mv | AT jinlingliu comparativeefficacyandacceptabilityofantidepressantsinparkinsonsdiseaseanetworkmetaanalysis AT jiangchuandong comparativeefficacyandacceptabilityofantidepressantsinparkinsonsdiseaseanetworkmetaanalysis AT leiwang comparativeefficacyandacceptabilityofantidepressantsinparkinsonsdiseaseanetworkmetaanalysis AT yingsu comparativeefficacyandacceptabilityofantidepressantsinparkinsonsdiseaseanetworkmetaanalysis AT pengyan comparativeefficacyandacceptabilityofantidepressantsinparkinsonsdiseaseanetworkmetaanalysis AT shenggangsun comparativeefficacyandacceptabilityofantidepressantsinparkinsonsdiseaseanetworkmetaanalysis |